Age at Diagnosis Indicated Poor Prognosis in Locoregionally Advanced Nasopharyngeal Carcinoma
Lu-Ning Zhang,Xing-Sheng Qiu,Pu-Yun OuYang,Yao Xiao,Xiao-Wen Lan,Wuguo Deng,Fang-Yun Xie,Xi-Cheng Wang
DOI: https://doi.org/10.18632/oncotarget.12544
2016-01-01
Oncotarget
Abstract:// Lu-Ning Zhang 1,2,* , Xing-Sheng Qiu 3,* , Pu-Yun OuYang 2,* , Yao Xiao 2 , Xiao-Wen Lan 2 , Wuguo Deng 2 , Fang-Yun Xie 2 and Xi-Cheng Wang 1 1 Department of Oncology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China 2 Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China 3 Department of Radiation Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China * Co-first authors Correspondence to: Xi-Cheng Wang, email: // Fang-Yun Xie, email: // Wuguo Deng, email: // Keywords : age; concurrent chemoradiotherapy; distant metastasis; mortality; nasopharyngeal carcinoma Received : August 10, 2016 Accepted : September 29, 2016 Published : October 09, 2016 Abstract Background: Effect of age at diagnosis on treatment failure and mortality was rarely evaluated in nasopharyngeal carcinoma. Methods: We analyzed 1252 patients staged III-IVb and underwent concurrent chemoradiotherapy. Age was categorized as 20 to 49 years ( n =804), 50 to 59 years ( n =282) and 60 years or older ( n =166). Distant metastasis-free survival (DMFS), cancer-specific survival (CSS), overall survival (OS) and locoregional relapse-free survival (LRFS) were assessed by age group. Results: The 4-years DMFS decreased with age group (86.7% [20-49 years], 86.7% [50-59 years], 77.1% [≥60 years]; P =0.014); likewise, 4-years CSS were 91.0%, 87.4% and 74.2% ( P <0.001); 4-years OS were 90.8%, 87.4% and 73.6% ( P <0.001), respectively. In multivariate analysis, compared with patients aged 20 to 49 years, DMFS decreased with age for patients aged 50 to 59 years (HR=1.10, 95% CI 0.77-1.57) and aged 60 years or older (HR=1.75, 95% CI 1.20-2.56) ( P =0.015). Similarly, both CSS and OS were inferior in patients aged 50 to 59 years (HR=1.77, 95% CI 1.25-2.52 for CSS; HR=1.71, 95% CI 1.21-2.43 for OS) and aged 60 or older (HR=3.73, 95% CI 2.63-5.29 for CSS; HR=3.96, 95% CI 2.83-5.54 for OS) ( P <0.001). Yet age did not affect LRFS in univariate and multivariate analysis. Conclusions: Increasing age at diagnosis of locoregionally advanced nasopharyngeal carcinoma was associated with higher risk of distant metastasis and mortality.